6.925  0.485 (7.53%)		10-22 11:57
Open: 6.58 High: 7.15 Volume: 1,616		Pre. Close: 6.4401 Low: 6.12 Market Cap: 29(M)

Short term
Mid term
Targets	6-month :	8.28	1-year :	9.16
Resists	First :	7.09	Second :	7.84
Pivot price	6.75
Supports	First :	5.86	Second :	4.88
MAs	MA(5) :	6.7	MA(20) :	6.76
	MA(100) :	7.06	MA(250) :	11.28
MACD	MACD :	-0.2	Signal :	-0.1
%K %D	K(14,3) :	43.6	D(3) :	53
RSI	RSI(14): 42.3
52-week	High :	33.29	Low :	3.63

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ TVGN ] has closed above bottom band by 14.8%. Bollinger Bands are 66.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	6.45 - 6.48	6.48 - 6.51
Low:	6.35 - 6.39	6.39 - 6.43
Close:	6.37 - 6.43	6.43 - 6.49

Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.

Wed, 21 Oct 2026
Tevogen Bio (TVGN) Slips 0.87% to $6.82 as Shares Test Lower End of Recent Range - Reversal Setup Alerts - https://www.siam.in/

Thu, 08 Oct 2026
Tevogen Bio Signs Letter of Intent to Evaluate HRK Healthcare Acquisition - Yahoo Finance

Wed, 30 Sep 2026
Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements - Yahoo Finance

Wed, 30 Sep 2026
Two rules for keeping Tevogen listed on Nasdaq are now met. - Stock Titan

Wed, 30 Sep 2026
Tevogen Bio Holdings Regains Compliance With Nasdaq Minimum Market Value Requirement - Yahoo Finance

Fri, 11 Sep 2026
Tevogen Bio regains Nasdaq listing compliance status - The Globe and Mail

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	7 (M)
Shares Float	1 (M)
Held by Insiders	72 (%)
Held by Institutions	1.6 (%)
Shares Short	56 (K)
Shares Short P.Month	60 (K)

EPS	-6.66
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-4.47
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-297.4 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-3.27
Qtrly Earnings Growth	0 %
Operating Cash Flow	-12 (M)
Levered Free Cash Flow	-3 (M)

PE Ratio	-0.97
PEG Ratio	0
Price to Book value	-1.44
Price to Sales	0
Price to Cash Flow	-3.61

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.